Screening tests of liver metastasis in patients with breast cancer.
| Sen (%) | Spe (%) | DI | CA | PV+ | PV- | α | β | LR+ | LR− | |
|---|---|---|---|---|---|---|---|---|---|---|
| LDH | 81.0 | 69.5 | 0.505 | 0.712 | 0.323 | 0.953 | 0.305 | 0.190 | 2.66 | 0.27 |
| GGT | 68.2 | 82.5 | 0.507 | 0.803 | 0.409 | 0.936 | 0.175 | 0.317 | 3.90 | 0.38 |
| CA153 | 52.0 | 80.8 | 0.328 | 0.758 | 0.377 | 0.886 | 0.192 | 0.480 | 2.71 | 0.59 |
| LDH and CA153 (serial test) | 37.1 | 97.7 | 0.348 | 0.875 | 0.765 | 0.885 | 0.023 | 0.629 | 16.13 | 0.64 |
| LDH and CA153 (parallel test) | 88.6 | 56.9 | 0.455 | 0.622 | 0.292 | 0.961 | 0.431 | 0.114 | 2.06 | 0.20 |
| GGT and CA153 (serial test) | 32.4 | 97.7 | 0.301 | 0.871 | 0.733 | 0.905 | 0.023 | 0.676 | 14.09 | 0.69 |
| GGT and CA153 (parallel test) | 85.7 | 56.4 | 0.421 | 0.615 | 0.291 | 0.950 | 0.436 | 0.143 | 1.97 | 0.25 |
LDH, lactate dehydrogenase; GGT, g-glutamyltransferase; CA153, carbohydrate antigen 153; Sen, sensitivity; Spe, specificity; DI, diagnostic index; a, false positive rate; b, false negative rate; CA, crude accuracy; PV+, positive predictive value; PV-, negative predictive value; LR+, likelihood ratio positive; LR-, likelihood ratio negative.